211 related articles for article (PubMed ID: 36656913)
1. Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition.
Li X; Wang F; Zhang X; Sun Q; Kuang E
PLoS Pathog; 2023 Jan; 19(1):e1011103. PubMed ID: 36656913
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
3. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
4. Effects of ER stress on unfolded protein responses, cell survival, and viral replication in primary effusion lymphoma.
Shigemi Z; Baba Y; Hara N; Matsuhiro J; Kagawa H; Watanabe T; Fujimuro M
Biochem Biophys Res Commun; 2016 Jan; 469(3):565-72. PubMed ID: 26692493
[TBL] [Abstract][Full Text] [Related]
5. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
Smith CG; Kharkwal H; Wilson DW
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
[TBL] [Abstract][Full Text] [Related]
6. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
Jiang Y; Xu D; Zhao Y; Zhang L
PLoS One; 2008 Feb; 3(2):e1569. PubMed ID: 18253508
[TBL] [Abstract][Full Text] [Related]
7. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression.
McHugh D; Caduff N; Barros MHM; Rämer PC; Raykova A; Murer A; Landtwing V; Quast I; Styles CT; Spohn M; Fowotade A; Delecluse HJ; Papoudou-Bai A; Lee YM; Kim JM; Middeldorp J; Schulz TF; Cesarman E; Zbinden A; Capaul R; White RE; Allday MJ; Niedobitek G; Blackbourn DJ; Grundhoff A; Münz C
Cell Host Microbe; 2017 Jul; 22(1):61-73.e7. PubMed ID: 28704654
[TBL] [Abstract][Full Text] [Related]
8. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
10. The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation.
Alzhanova D; Meyo JO; Juarez A; Dittmer DP
J Virol; 2021 Nov; 95(23):e0145921. PubMed ID: 34523970
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
Zhang YJ; Patel D; Nan Y; Fan S
Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
[TBL] [Abstract][Full Text] [Related]
12. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
Watanabe T; Fujimuro M
Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
[TBL] [Abstract][Full Text] [Related]
13. Targeting FoxO proteins induces lytic reactivation of KSHV for treating herpesviral primary effusion lymphoma.
Lan J; Wang Y; Yue S; Xu D; Li Y; Peng X; Hu J; Ju E; He S; Li T
PLoS Pathog; 2023 Aug; 19(8):e1011581. PubMed ID: 37594999
[TBL] [Abstract][Full Text] [Related]
14. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.
Kim YJ; Kim Y; Kumar A; Kim CW; Toth Z; Cho NH; Lee HR
PLoS Pathog; 2021 Jan; 17(1):e1009179. PubMed ID: 33471866
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
16. Nm23-H1 induces apoptosis in primary effusion lymphoma cells via inhibition of NF-κB signaling through interaction with oncogenic latent protein vFLIP K13 of Kaposi's sarcoma-associated herpes virus.
Mohanty S; Kumar A; Das P; Sahu SK; Mukherjee R; Ramachandranpillai R; Nair SS; Choudhuri T
Cell Oncol (Dordr); 2022 Oct; 45(5):967-989. PubMed ID: 35964258
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.
Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E
mBio; 2020 Aug; 11(4):. PubMed ID: 32843547
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.
Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C
J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900
[TBL] [Abstract][Full Text] [Related]
19. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
[TBL] [Abstract][Full Text] [Related]
20. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
